Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT…
ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation…
Shimadzu Asia Pacific Celebrates 150th Anniversary -A Century and a Half of Driving Healthcare and Technological Breakthroughs
SINGAPORE, Oct. 21, 2025 /PRNewswire/ -- Shimadzu Asia Pacific joins the global…
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM),…
Aletheia Capital Endeavours Launches RepIntel, a Campaign-Grade Platform to Accelerate Global Access to Therapies
October 24, 2025 23:37 ET | Source: RepIntel. New York, New York,…
Cipla Health welcomes FSSAI’s new labelling rules for ‘ORS’, reinforces Prolyte ORS as the #AsliORS
MUMBAI, India, Oct. 24, 2025 /PRNewswire/ -- ProlyteORS, the flagship brand of…
Berlin Heals Welcomes Dr. Eric Fain as New Board Member
Berlin Heals adds MedTech Veteran Dr. Eric Fain to Board of Directors…
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
October 24, 2025 07:02 ET | Source: Kura Oncology, Inc. - Milestone…
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
October 24, 2025 07:00 ET | Source: Sagimet Biosciences Inc. Denifanstat met…
Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes
LEHI, Utah, Oct. 23, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical…